SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes

Article Endocrinology & Metabolism

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023

Nuha A. ElSayed et al.

DIABETES CARE (2023)

Article Endocrinology & Metabolism

Different Sodium-Glucose Cotransporter-2 Inhibitors: Can They Prevent Death

Pradip Mukhopadhyay et al.

Summary: The meta-analysis suggests that SGLT2is as a class reduce both all-cause mortality and cardiovascular mortality, with some variations in effectiveness seen among different individual SGLT2is.

ENDOCRINE PRACTICE (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies et al.

Summary: The American Diabetes Association and the European Association for the Study of Diabetes have updated the consensus statements on the management of hyperglycemia in adults with type 2 diabetes. The new recommendations highlight the importance of social determinants of health, weight management, and provide practical tips for implementation.

DIABETES CARE (2022)

添加到收藏夹

Article Medicine, General & Internal

SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

Muthiah Vaduganathan et al.

Summary: This study conducted a meta-analysis of the therapeutic effects of SGLT2 inhibitors in heart failure patients, showing that these drugs can significantly reduce the risk of cardiovascular death and hospitalization for heart failure in heart failure patients, demonstrating their importance in foundational treatment.

LANCET (2022)

添加到收藏夹

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Deepak L. Bhatt et al.

Summary: The trial involving 10,584 patients with diabetes and chronic kidney disease showed that sotagliflozin resulted in fewer deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure compared to placebo. However, there were adverse events such as diarrhea, mycotic infections, and diabetic ketoacidosis associated with sotagliflozin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis

Wen-Hsuan Tsai et al.

Summary: The meta-analysis results showed that SGLT2 inhibitors have a neutral effect on the risk of stroke and its subtypes, but may have a potential protective effect against hemorrhagic stroke.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Medicine, General & Internal